Korsana Biosciences, Inc.

Korsana Biosciences is committed to building best-in-class therapeutics with the goal of reducing the burden of neurodegenerative diseases for patients and caregivers. The Company’s lead program, KRSA-028, is a next-generation shuttled antibody targeting amyloid beta for the treatment of Alzheimer’s disease. KRSA-028 leverages Therapeutic Targeting (THETA™), a novel CNS shuttle technology developed in partnership with Paragon Therapeutics and designed to enable dramatically higher drug concentrations in the brain and overcome the limitations of earlier shuttle technologies. In addition, Korsana is advancing a pipeline of innovative therapies for neurodegenerative diseases. For more information, please visit www.korsana.com and follow the Company on LinkedIn.

Current securities

1. Entry into a Material Definitive Agreement · Completion of Acquisition or Disposition of Assets · Results of Operations and Financial Condition · Unregistered Sales of Equity Securities · Material Modification to Rights of Security Holders · Changes in Control of Registrant · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics · Change in Shell Company Status · Regulation FD DisclosureSep 11, 2026
2. 4 filingSep 10, 2026
3. 3 filingSep 10, 2026
4. 3 filingSep 10, 2026
5. 3 filingSep 10, 2026